Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note released on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

Minerva Neurosciences Stock Down 0.4 %

Shares of Minerva Neurosciences stock opened at $2.35 on Friday. Minerva Neurosciences has a 52 week low of $2.06 and a 52 week high of $13.49. The company has a market capitalization of $16.43 million, a price-to-earnings ratio of -5.34 and a beta of 0.11. The stock’s 50-day simple moving average is $2.26 and its 200-day simple moving average is $2.65.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.